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damage—though these occurred less commonly (<10% of
patients each). The analyses also revealed signiﬁcantly increased
relative risk (25–100%) for non-psychiatric disorders involving
immune mechanisms, neurological disorders, metabolic disor-
ders, diseases of the skin and ear, pulmonary and upper respira-
tory diseases, certain gastrointestinal disorders, diseases of the
blood and blood-forming organs, and accidents and injuries (all
p < 0.001). Detailed ﬁndings by age and gender will be presented.
CONCLUSIONS: These data indicate substantial comorbidity
associated with ADHD in children and adolescents. They
provide a basis for further epidemiological research and for
analyses of the cost associated with ADHD.
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OBJECTIVE: To estimate the cost-effectiveness of atomo-
xetine for the treatment of children and adolescents with 
Attention Deﬁcit/Hyperactivity Disorder (ADHD) in Norway.
METHODS: A modeled economic evaluation calculated the
incremental cost per quality-adjusted life years (QALYs) gained
of atomoxetine compared to two stimulant therapies and “no
medication”. Treatment algorithms with and without atomoxe-
tine were compared in patient subgroups stratiﬁed by prior treat-
ment history and whether stimulant medication was appropriate.
A Markov process incorporated fourteen health states repre-
senting hypothetical treatment outcomes for which utility values
were sought from parents of patients through survey. Aspects of
effectiveness and safety of each medication were based on a
review of controlled clinical trials and other clinical literature.
Monte-Carlo simulation was run over a one-year duration from
the perspective of the Norwegian health care system. RESULTS:
In stimulant-naive patients, the incremental cost per QALY of
atomoxetine was NOK 199,178 and NOK 149,892 when com-
pared to immediate-release (IR) and extended-release (XR)
methylphenidate, respectively. In stimulant-failed patients, the
incremental cost-effectiveness of atomoxetine was NOK 168,154
per QALY gained. The incremental cost per QALY of atomoxe-
tine compared to no medication in patients contra-indicated for
stimulants was NOK 175,105. Sensitivity analysis showed that
the utility values for each treatment were important determinants
of the cost-effectiveness of atomoxetine. CONCLUSIONS:
Results of the modeled economic evaluation suggest atomoxe-
tine offers a value-for-money alternative in the treatment of 
children with ADHD in Norway.
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The U.S. MTA Study represents the most important randomized
trial of ADHD treatment strategies that has undergone economic
evaluation. Yet there are distinct differences between the United
States and Germany regarding diagnostic criteria, treatment pref-
erences, health care utilization patterns, and unit costs related to
ADHD. OBJECTIVE: To evaluate, based on the MTA, the cost-
effectiveness of clinically proven treatment strategies for ADHD
from the perspective of the statutory health insurance (SHI) in
Germany, and to provide cost-utility estimates. METHODS: A
total of 579 children with ADHD, combined type (DSM-IV),
aged 7–10, were assigned to 14 months of routine community
care (CC), medication management (MedMgt), intensive behav-
ioral treatment (Beh), or the two combined (Comb). Diagnostic
data were used to identify patients meeting the stricter ICD-10
criteria for Hyperkinetic (Conduct) Disorder (HKD, F90.0, or
HKCD, F90.1; n = 145). Clinical effectiveness was determined
using ADHD symptom normalization rates, and utility estimates
came from the literature. Costs were calculated for resources
used, excluding the research component of the study, using
current (2005) SHI acquisition costs. Time horizon of the analy-
sis was one year. RESULTS: MedMgt, compared to CC, led 
to an incremental cost per patient normalized of €2088 (or
€17,850-32,630/QALY), dominating the Beh strategy. Comb,
compared to MedMgt, was associated with an ICER of €55,441
Euro per patient normalized. Deterministic and stochastic sensi-
tivity analyses (by nonparametric bootstrapping) demonstrated
the robustness of these ﬁndings over a broad range of assump-
tions, including less costly routine care. CONCLUSIONS:
Despite substantial differences in ADHD diagnosis and treat-
ment between the U.S. and Germany, these results for Germany
concur with overall U.S. ﬁndings in clearly showing dominance
of MedMgt compared to Beh for HKD/HKCD. Based upon the
MTA, adding intensive Beh to MedMgt (“Comb”) in patients
with HKD/HKCD is associated with an estimated cost per QALY
gained in the range of €474,000–866,000.
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OBJECTIVES: To measure the social and economic burden of
ADHD in the perspective of families, NHS and Italian society.
METHODS: Cost of illness and quality of life analysis based on
an observational case-control, parallel groups, retrospective data
collection on the use of medical resources and social services over
12 months. The study underwent EC approval and informed
consent was obtained. Consecutive patients of age 5 to 18 years,
were recruited at 4 neuro-psychiatry clinics, and allocated to 
4 groups: K (controls) including subjects with mild anxiety/
depression (C-GAS < 50); A, subjects with recently diagnosed
ADHD; B, ADHD managed by psycho-educational interven-
tions; C ADHD managed by pharmacological treatment+psyco-
educational interventions. Resource utilisation was measured
with a structured questionnaire administered to parents and QoL
with the CHIP-CE, Parent Form. RESULTS: (Only ADHD data
vs. controls are presented) 244 subjects were enrolled: K = 69
age = 12.2yrs (SD + 3.3), ADHD = 175 age = 10.9 (SD + 2.6).
ADHD patients were mostly male children, living in large, well-
off families showing higher probability vs. controls of needing
hospital admissions (OR = 3.0; 95%IC 1.4–6.3, p = 0.005), psy-
chologist consultations (OR = 4.9; 95%IC 2.2–10.9, p < 0.001),
lab tests (OR = 2.6; 95%IC 1.4–4.7, p = 0.005) and ECG (OR
= 2.2; 95%IC 1.2–4.2, p = 0.011). ADHD patients also showed
